International validation of a behavioral scale in Parkinson's disease without dementia

Movement Disorders

Volumn 30, Issue 5, 2015, Pages 705-713

  Rieu, Isabelle ^a,b   Martinez Martin, Pablo ^c   Pereira, Bruno ^d   De Chazeron, Ingrid ^a,b   Verhagen Metman, Leo ^e   Jahanshahi, Marjan ^f   Ardouin, Claire ^g   Chéreau, Isabelle ^a   Brefel Courbon, Christine ^h   Ory Magne, Fabienne ^h   Klinger, Helene ⁱ   Peyrol, Fleur ^d   Schupbach, Michael ^j   Dujardin, Kathy ^k   Tison, François ^l   Houeto, Jean Luc ^m,n   Krack, Paul ^g   Durif, Franck ^a,b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e RUSH MEDICAL COLLEGE   (United States)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ HÔPITAL NEUROLOGIQUE   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k UNIV LILLE   (France)

^l UNIVERSITÉ DE BORDEAUX   (France)

^m POITIERS UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITÉ DE POITIERS   (France)

more..

Author keywords

Clinical trials; Neuropsychological and behavioral assessments; Observational study; Parkinson's disease; Psychiatric disorders

Indexed keywords

ADULT; APATHY; ARTICLE; CONSTRUCT VALIDITY; CROSS-SECTIONAL STUDY; DEMENTIA; DSM-IV; FEMALE; HIGH RISK BEHAVIOR; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPERSEXUALITY; MAJOR CLINICAL STUDY; MALE; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; REPRODUCIBILITY; TEST RETEST RELIABILITY; UNIFIED PARKINSON DISEASE RATING SCALE; UNITED STATES; AGED; BEHAVIOR; CLINICAL TRIAL; COMPLICATION; DIAGNOSIS; ETIOLOGY; FACTORIAL ANALYSIS; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY;

AGED; BEHAVIORAL SYMPTOMS; CROSS-SECTIONAL STUDIES; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS;

EID: 84926624886     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26223     Document Type: Article

References (54)

1. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009;24:2175-2186.
2. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson's disease. Mov Disord 2007;22:778-784.
3. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008;23:183-189.
4. Dissanayaka NN, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010;25:838-845.
5. Pedersen KF, Larsen JP, Alves G, Aarsland D. Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. Parkinsonism Relat Disord 2009;15:295e9.
6. Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009;24:1333-1338.
7. Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis 2012;46:581-589.
8. Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson's disease. Neurodegener Dis 2013;11:63-71.
9. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-595.
10. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: on movement, mood, and madness. Mov Disord 2009;24:1255-1266.
11. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.
12. Figiel G, Sadowsky C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin 2008;24:157-166.
13. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-973.
14. Brooks DJ, Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol 2011;95:614-628.
15. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.
16. Lhommée E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012;135:1463-1477.
17. Czernecki V Schüpbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008;23:964-969.
18. Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:868-874.
19. Thobois S, Ardouin C, Schmitt E, et al. Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment. Rev Neurol (Paris) 2010;166:816-821.
20. Thobois S, Lhommée E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013;136:1568-1577.
21. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
22. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004;17:393-398.
23. Cubo E, Benito-León J, Coronell C, Armesto D; ANIMO Study Group. Clinical correlates of apathy in patients recently diagnosed with Parkinson's disease: the ANIMO study. Neuroepidemiology 2012;38:48-55.
24. Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol 2005;96:42-55.
25. Molina JA, Sáinz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000;15:869-872.
26. Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007;21:501-506.
27. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524-529.
28. Witjas T, Kaphan E, Azulay JP, et al. Non motor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-413.
29. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005;20:726-733.
30. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
31. Sockeel P, Dujardin K, Devos D, Denève C, Destée A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:579-584.
32. Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009;24:1461-1467.
33. Martinez-Martin P, Frades-Payo B, Agüera-Ortiz L, Ayuga-Martinez A. A short scale for evaluation of neuropsychiatric disorders in Parkinson's disease: first psychometric approach. J Neurol 2012;259:2299-2308.
34. Ardouin C, Chéreau I, Llorca PM, et al. Assessment of hyper- and hypo-dopaminergic behaviors in Parkinson's disease. Rev Neurol (Paris) 2009;165:845-856.
35. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
36. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
37. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
38. Fahn S et al. In: Fahn S, Marsden CD, Calne D, Golstein N, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Health Care Information, 1987:153-163.
39. Bech P, Bolwig TG, Kramp P, Rafaelsen OJ. The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand 1979;59:420-430.
40. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
41. McElroy PE, Keck PE Jr, Pope HG Jr, Smith JM, Strakowski SM. Compulsive buying: a report of 20 cases. J Clin Psychiatry 1994;55:242-248.
42. DSM-IV-TR, 4th ed. Washington: American Psychiatric Association, 2000.
43. Carnes P. Sexual addiction screening test. Tenn Nurse 1991;54:29.
44. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
45. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33.
46. Landis JR, Koch GG. The measurement of observer agreement for categorical data; Biometrics 1977;33:159-174.
47. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998;2:1-74.
48. Browne MW. An overview of analytic rotation in exploratory factor analysis. Multivariate Behavioral Research 2001;36:111-150.
49. Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for impulsive-compulsive disorders in Parkinson's disease-rating scale; Mov Disord 2012;27:242-247.
50. Ryback RS, Schwab RS. Manic response to levodopa therapy: report of a case. N Engl J Med 1971;285:788-789.
51. Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson's disease. Neurology 2006;67:33-38.
52. Kummer A, Maia DP, Salgado JV, Cardoso FE, Teixeira AL. Dopamine dysregulation syndrome in Parkinson's disease: case report. Arq Neuropsiquiatr 2006;64:1019-1022.
53. Spencer AH, Rickards H, Fasano A, Cavanna AE. The prevalence and clinical characteristics of punding in Parkinson's disease. Mov Disord 2011;26:578-586.
54. Fasano A, Petrovic I. Insights into pathophysiology of punding reveal possible treatment strategies. Mol Psychiatry 2010;15:560-573.